Sareum Holdings PLC Phase 1a clinical trial for SDC-1801 (8615Z)
May 18 2023 - 2:00AM
UK Regulatory
TIDMSAR
RNS Number : 8615Z
Sareum Holdings PLC
18 May 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum announces the commencement of a Phase 1a clinical trial
for SDC-1801
Cambridge, UK , 18 May 2023 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next generation
kinase inhibitors for autoimmune disease and cancer, today
announces the initiation of a Phase 1a clinical trial for its lead
product SDC-1801. The trial has started with patient recruitment in
progress at specialist clinical units located in Victoria,
Australia.
SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential
new therapeutic for a range of autoimmune diseases with an initial
focus on psoriasis, an autoimmune condition affecting the skin.
This follows the recent approval of the Company's application
under the Clinical Trial Notification (CTN) scheme by the Human
Research Ethics Committee (HREC). Australia's medicines regulator,
the Therapeutic Goods Administration (TGA), has also acknowledged
the application, allowing for the Phase 1a trial to proceed.
The initial Phase 1a trial is designed to investigate the safety
and pharmacokinetics of an oral formulation of SDC-1801 in healthy
subjects (trial ID ACTRN12623000416695p ). Provided satisfactory
safety data are obtained from this initial study, a Phase 1b
clinical study is expected to commence in psoriasis patients in
2024 .
-Ends-
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Lauren Williams, Head of Investor Relations ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel / Oliver Duckworth 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce 020 3764 2341
Consilium Strategic Communications (Financial
PR)
Jessica Hodgson / Davide Salvi / Stella
Lempidaki 020 3709 5700
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology
company developing next generation kinase inhibitors for autoimmune
disease and cancer.
The Company is focused on developing next generation small
molecules which modify the activity of the JAK kinase family and
have best-in-class potential. Its lead candidate, SDC-1801,
simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential
treatment for a range of autoimmune diseases and has entered Phase
1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1
inhibitor which it originally developed in collaboration with
several Cancer Research UK-related organisations. SRA737 has shown
promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a
potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on
the AIM market of the London Stock Exchange, trading under the
ticker SAR. For further information, please visit the Company's
website at www.sareum.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGUGDURUBDGXI
(END) Dow Jones Newswires
May 18, 2023 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2023 to Apr 2024